Fusion Antibodies: results underwhelm
Fusion Antibodies (LON: FAB), specialists in pre-clinical antibody discovery, for both therapeutic drug and diagnostic applications, underwhelmed with its interim results for the six months ending 30 September 2020, at least for a business with its high rating – the current market capitalisation is £29m.
Revenues rose 8.5% of £1.90m with losses remaining stable at £0.47m.
They expanded their R&D programme in the period by 50% to £271k to include a COVID-19 target…
Sign up and read the full article
Register to continue reading our content.
Get FREE access now
Already a member? Login
Previous article
Next article
More on Advanced Medical Solutions
16/03/2024 · Podcasts
This episode discusses Bitcoin's surging price, the UK competition authority's probe into the veterinary sector, Trainline's growth and…
13/03/2024 · Company Insights
We pick through the latest results from two of AIM’s world leaders. The shares of both…
More on Argentex Group PLC
03/02/2024 · Podcasts
In this episode of the Investor’s Champion Podcast, Chris and Lee run through key news from…
30/01/2024 · Company Insights
Even in the most challenging of markets this business still generated significant profits and continued to pay…
More on Frasers Group
05/01/2024 · Portfolio
Our portfolio company covered here dominates the market for athletic footwear, but is it the best…
28/06/2023 · Company Insights
Having experienced a dramatic rise and fall over the past decade, Mulberry faces an uncertain future.…
More on Fusion Antibodies PLC
20/11/2020 · Company Insights
Mike Ashley’s Frasers has upped its stake in Mulberry and is obliged to contemplate a full…
28/04/2020 · Company Insights
Announcements included an update from from Burford Capital, which saw its shares bounce strongly, but we still…
More Company Insights
Results include commendable returns from an AIM elder
Doing well in the biggest market of all
Another upgrade and strong results for our bargain stocks
More on Advanced Medical Solutions
More on Argentex Group PLC
More on Frasers Group
More on Fusion Antibodies PLC
More Company Insights